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Abstract
Background: The incidence of non-alcoholic fatty liver disease (NAFLD), commonly associated with obesity and
metabolic syndrome, is increasing worldwide. However, the specific mechanisms that mediate the progression from
simple steatosis to non-alcoholic steatohepatitis remain largely unclear. This study aimed to investigate the
timedependent changes of triglyceride (TG) and free fatty acid (FFA) levels in the blood and liver over 24 weeks in
high-fat diet-induced obese rats with NAFLD and to clarify the role of high FFA levels in the progression of liver
injury.
Methods: Male Wistar rats were randomly divided into three groups (n = 30 per group): the Control group, fed
standard chow; the High-fat diet (HFD) group, fed high-fat chow; and the Acipimox group, fed an HFD plus
acipimox (100 mg/kg/d, ig) for 8, 16 and 24 weeks. After treatment, blood and liver samples were collected for
biochemical analyses, western blotting analysis and a histopathological study.
Results: The visceral fat/weight and liver/body weight ratios were higher in both the HFD and Acipimox groups than in
the Control group. The TG and FFA concentrations in blood and liver were increased in the HFD group and associated
with elevated serum alanine aminotransferase (ALT) and liver malondialdehyde (MDA) levels and macro/microvesicular
steatosis on hepatic fragments. Although the TG levels in the liver were similar between the HFD and Acipimox groups
(p > 0.05), the FFA concentrations in the blood and liver were much lower in the latter group (p< 0.05). The Acipimox
group showed normal ALT and MDA levels as well as less severe hepatic histological changes than did the HFD group
(NAFLD activity score: 2.14 ± 0.14, 2.43 ± 0.20 and 2.63 ± 0.26 at 8, 16 and 24 weeks, respectively; p < 0.05 versus the HFD
group at 24 weeks). The diacylglycerol acyltransferase 2 (DGAT2) protein levels were similar between the HFD and
Acipimox groups (p> 0.05), but the protein expression level of carnitine palmitoyltransferase 1a (CPT-1a) was higher in the
Acipimox group.
Conclusions: Liver TG accumulation does not cause cellular injury in the liver; rather, FFAs or their metabolites are
responsible for liver injury via increased oxidative stress. It is suggested that the therapeutic efforts to prevent non-
alcoholic liver injury progression should be focused on reducing the burden of fatty acids transported to the liver or
those being synthesized in the liver.
Keywords: Non-alcoholic fatty liver disease, Free fatty acids, Triglycerides, Oxidative stress, Lipid metabolism
* Correspondence: yerongyu@scu.edu.cn
Department of Endocrinology and Metabolism, West China Hospital, Sichuan
University, Guoxue lane 37, Chengdu, Sichuan 610041, China
© 2016 Liu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Liu et al. Lipids in Health and Disease  (2016) 15:27 
DOI 10.1186/s12944-016-0194-7
Background
Non-alcoholic fatty liver disease (NAFLD) has rapidly
become the most common cause of chronic liver disease
worldwide. Clinical epidemiological data indicate that
the prevalence of NAFLD ranges from 20 % to 30 % in
Western countries and is 15 % in Asian countries [1].
NAFLD encompasses a spectrum of histological findings
ranging from steatosis to steatohepatitis, and steatohepa-
titis can eventually progress to cirrhosis and even hepa-
tocellular carcinoma [2, 3]. By some estimates, 10 ~ 20 %
of patients with simple steatosis will convert into non-
alcoholic steatohepatitis (NASH) [4] and 1.5 % to 3 %
will develop advanced liver fibrosis [5], which seriously
threatens the health of patients. Thus, to reduce the
development of NASH and liver fibrosis/ cirrhosis, it is
necessary to explore the pathophysiology and risk factors
that influence the progression from simple fatty liver to
NASH and to formulate early intervention strategies.
Although the model of the “two-hit theory” is widely ac-
cepted to explain the pathogenesis of NAFLD, the specific
mechanisms that mediate the progression from simple
steatosis to non-alcoholic steatohepatitis and those that
lead the maintenance of simple steatosis in some patients
are poorly understood. The presence of steatosis is a pre-
requisite for NASH, but it is not causal for the develop-
ment of NAFLD. Some recent studies have found that
lipid accumulation in the liver may be a protective mech-
anism for patients with obesity/insulin resistance/elevated
free fatty acids (FFAs) [6, 7]. Hepatocytes, exposure to
high levels of circulating FFAs, and stored FFAs in the
form of triglycerides (TGs) may ease FFA-induced oxida-
tive stress and chronic inflammation, thereby preventing
further hepatocellular damage. However, whether elevated
FFA levels in the bloodstream play a key role in the patho-
genesis of NAFLD and whether lowering plasma and liver
FFA levels can exert a protective effect on hepatocytes
remains unclear.
Thus, to clarify the role of high FFA concentration in
the progression of NAFLD, we induced NAFLD in rats
using a high-fat diet and observed the time-dependent
changes of TG, FFAs, liver enzymes, oxidative stress
levels, and the protein expression levels related to TG
synthesis and fatty acid oxidation. In addition, we uti-
lized acipimox, a lipolysis inhibitor, to reduce blood FFA
levels [8, 9] and determined whether reduced FFA levels
had a protective effect on the liver.
Methods
Study animals and treatments
Eight-week-old male Wistar rats weighing 270 ± 10 g
were obtained from the animal resources centre (Sichuan
University, China). All of the protocols were approved by
the Ethic Committee of West China Hospital, and the
animals were handled according to the “Principles of
Laboratory Animal Care.” The animals were maintained on
a 12-h light/dark cycle with controlled room temperature
(20 ± 2 °C) and had access to food and water ad libitum.
After an adaptation period of 1 week, the rats were
randomly divided into three groups: (1) the Control group
(n = 30), fed standard rat chow; (2) the High-fat diet (HFD)
group (n = 30), fed high-fat chow; and (3) the Acipimox
group (n = 30), fed high-fat chow plus acipimox (100 mg/
kg/day, ig). The percentages of grams and energy of the
macronutrients in the diets are listed in Table 1. Body
weight was measured weekly during the feeding period and
compared with liver weight and visceral fat mass after the
animals were sacrificed.
At the end of 8, 16, and 24 weeks, 10 rats in each of
the three groups were sacrificed under pentobarbital so-
dium anaesthesia. On the day prior to sacrifice, the rats
were subjected to overnight fasting. Blood samples were
obtained from the heart by cardiac puncture, and serum
samples were preserved at −80 °C for biochemical ana-
lyses as described below. Liver samples were weighed
and processed for biochemical and histopathological
studies and western blotting analysis. Abdominal visceral
fat (including perirenal, epididymal, and mesenteric fat)
was collected and weighed.
Blood biochemical analysis
The total cholesterol (TC) and TG levels were deter-
mined using enzymatic assays in commercial kits (Huili
Biotechnologies Inc., Changchun, China). The FFA levels
were assayed using the colorimetric method with a serum
FFA kit (E1001, Applygen Technologies Inc., Beijing,
China). The serum ALT activity, a biomarker for liver
damage, was measured using an ELISA and a rat ALT kit.
Assessments of hepatic TGs and FFAs
The liver TG (LTG) concentrations were quantified using a
commercially available tissue TG kit (E1013, Applygen
Technologies Inc., Beijing, China). Fatty acids were ex-
tracted from the liver using previously described methods
[10, 11]. Briefly, 0.2 g of liver was weighed and placed into a
manual glass homogenizer with lysis buffer (200 μL of
20 mM EDTA, 2 mM NaCl, and 50 mM sodium phosphate
buffer, pH 7.4). Next, 10 μL of homogenate was mixed with
10 μL of tert-butyl alcohol and 5 μl of Triton X-100/methyl
alcohol mixture (1:1 vol/vol) for lipid extraction [11]. The
Table 1 Compositions of the chow and high-fat diets
Chow diet High-fat diet
g % kcal % g % kcal %
Carbohydrate 60 67.4 21 15.8
Fat 4 10.1 39 66.1
Protein 20 22.5 24 18.1
Kcal/g 3.56 5.31
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FFAs were measured using an enzymatic method. The pro-
tein concentrations in the liver extracts were determined
using the BCA protein assay kit.
Determination of malondialdehyde (MDA) and
glutathione peroxidase (GSH-Px) in liver tissues
The levels of MDA in the liver tissue were determined
using the thiobarbutaric acid (TBA) method with a com-
mercially available kit (Jiancheng Bioengineering Institute,
Nanjing, China), and the activity of GSH-Px was measured
using the velocity method with a GSH-Px kit (Jiancheng
Bioengineering Institute, Nanjing, China).
Liver histopathology
Hepatic tissue was removed from each rat, and the same
part of each liver was dissected, fixed in 10 % formalin,
and then embedded in paraffin wax for staining with
haematoxylin and eosin (H&E) and Masson’s trichrome.
Coded sections were examined for histopathological
changes by an experienced pathologist. Liver steatosis
and NAFLD activity scores were semi-quantitatively
evaluated as previously reported [12]. In brief, steatosis
scores were defined as follows: score 0, presence of
intrahepatic fat droplets in <5 % of hepatocytes; score 1,
presence of intrahepatic fat droplets in 5–33 % of hepa-
tocytes; score 2, presence of intrahepatic fat droplets in
33–66 % of hepatocytes; and score 3, presence of intra-
hepatic fat droplets in >67 % of hepatocytes. The
NAFLD activity score is the sum of three equal weighted
features: steatosis (0–3), lobular inflammation (0–3) and
hepatocellular ballooning (0–2).
Western blotting analysis
For the western blot analysis, 50 mg of hepatic tissue
was homogenized on ice in radioimmunoprecipitation
lysis buffer containing a complete protease inhibitor
cocktail (Roche Diagnostics). The homogenates were
centrifuged to collect the supernatants. The protein con-
centration was determined using a BCA protein assay
kit (Thermo Scientific). Protein samples were subjected
to SDS-PAGE and transferred onto polyvinylidene
difluoride (PVDF) membranes. After being blocked with
5 % bovine serum albumin in PBST at room temperature
for 2 h, the membranes were incubated with anti-
DGAT2 antibodies (rabbit anti-DGAT2; 1:400; Santa
Cruz Biotechnology) and anti-CPT-1a antibodies (rabbit
anti-CPT-1a; 1:400; Santa Cruz Biotechnology) at 4 °C
overnight. Subsequently, the membranes were washed
three times with PBST and incubated with the relevant
secondary HRP-conjugated antibodies (1:5000; ZSGB-
BIO, Beijing, China) for 90 min. β-actin (mouse anti-β-
actin; 1:500; ZSGB-BIO, Beijing, China) was used as the
loading control. The intensity was measured using
Quantity One densitometric software (Bio-Rad).
Statistical analysis
All results are expressed as means ± standard error.
Significant differences between the groups were deter-
mined using one-way analysis of variance (ANOVA)
followed by Scheffe’s post hoc test using the SPSS 16.0




As shown in Table 2, the body weight and visceral fat mass
of the rats in each group increased with age. At 8 weeks,
rats in both the HFD and Acipimox groups exhibited
higher visceral fat mass and a higher visceral fat/weight ra-
tio than did the age-matched control group, although no
statistically significant differences were observed in body
weight among the three groups. This phenomenon was
more significant at the end of 16 and 24 weeks, when body
weight, visceral fat mass, and the visceral fat/weight ratio in
both the HFD and Acipimox groups were all markedly in-
creased compared with the corresponding values in the
Control group (p < 0.05). The liver/body weight ratio in the
Control group did not change with time, whereas it was
much higher in the HFD and Acipimox groups (p < 0.05).
At 24 weeks, rats in the Acipimox group exhibited lower
visceral fat mass and a lower visceral fat/weight ratio than
did the rats in the age-matched HFD group, and no signifi-
cant differences were observed between the HFD and
Acipimox groups with respect to body weight or the liver/
body weight ratio during the study period (p > 0.05).
Serum biochemical analysis
As shown in Table 3, rats fed an HFD displayed higher
circulating levels of TGs, TC, and FFAs than did the
Control group rats. After 8 weeks, the serum TG levels
in the HFD group increased approximately 3.4-fold com-
pared to the Control group, whereas the FFA concentra-
tion only increased by 48 % in the HFD group; no
significant difference was observed between the HFD
and Control groups with respect to circulating TC levels.
By 24 weeks, the HFD group showed a 2.2-fold increase
in serum TG levels and a 56 % increase in serum TC
levels, and the serum FFA concentration of the HFD
group had increased to 2.7-fold that of the Control
group. Acipimox treatment decreased the concentrations
of TC, TG and FFAs compared to the HFD rats by 16
and 24 weeks (p < 0.05), and no significant differences
were observed between the Acipimox and Control
groups at any time point (p > 0.05) regarding the circu-
lating lipid profile.
The serum ALT levels in the Control group remained
stable during the study period (142 ± 2.3, 146 ± 4.4, and
144 ± 3.4 IU/L at 8, 16 and 24 weeks, respectively). The
ALT level was 141 ± 3.7 IU/L in the HFD group at
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8 weeks and increased progressively over time. By 16
and 24 weeks, the circulating ALT levels in the HFD
group reached 155 ± 5 and 170 ± 4.0 IU/L, respectively.
Compared to the Control group, HFD treatment caused
an 18 % increase in the serum ALT level at the end of
24 weeks (p < 0.05). The serum ALT levels in the Acipi-
mox group were 142 ± 2.6, 154 ± 4.4, and 150 ± 2.7 IU/L
by 8, 16 and 24 weeks, respectively, and these findings
were consistent with the levels observed in the Control
group (p > 0.05).
Hepatic TG and FFA contents
Both the HFD and Acipimox groups exhibited signifi-
cantly higher liver TG levels than did the Control group.
By 8, 16 and 24 weeks, the hepatic TG levels were 4.3-,
4.5- and 2.4-fold higher in the HFD group than in the
Control group. No significant differences were observed
in liver TG level between the Acipimox and HFD groups
during the study period. The HFD treatment progressively
increased the concentrations of hepatic FFAs over time.
The liver FFA level in the HFD group increased by 38 % at
16 weeks and by 57 % at 24 weeks relative to the level in
the Control group. Acipimox can effectively reduce the
hepatic FFA content, and no difference in liver FFA level
was detected between the Acipimox and Control groups
at 8 and 16 weeks. By 24 weeks, the Acipimox group
showed a slightly higher hepatic FFA content than did the
Control group, but this difference did not reach statistical
significance, and the hepatic FFA level in the Acipimox
group was still significantly lower than that of the HFD
group (Fig. 1).
Changes in MDA and GSH-Px concentrations in the liver
As shown in Table 4, the concentration of hepatic MDA
progressively increased in the HFD group over the
24 weeks. By 16 and 24 weeks, the liver MDA levels were
2.5- and 3-fold higher in the HFD group than in the Con-
trol group. Acipimox treatment markedly decreased the
liver MDA levels compared with the HFD group (p <
0.05). After 16 weeks, the Acipimox group exhibited
higher liver MDA levels than did the Control group, and
no difference was observed between the Acipimox and
Control groups regarding the hepatic MDA levels at 8 and
24 weeks.
Rats in the HFD and Acipimox groups all displayed
lower liver GSH-Px activity than did the Control group
at 8 and 16 weeks (p < 0.05). After 24 weeks, no signifi-
cant difference in hepatic GSH-Px activity was detected
among the three groups.
Changes in the TG synthesis and FFA oxidation rate-
limiting enzymes in the liver
To understand the potential in vivo mechanisms that in-
duced the changes in liver TG and FFA levels, we measured
the hepatic protein expression levels of DGAT2, a TG syn-
thesis rate-limiting enzyme, and the FFA oxidation-related
enzyme CPT-1a. The HFD and Acipimox groups exhibited
pronounced increases in DGAT2 protein level compared
with the Control group. At the end of 16 and 24 weeks, the
Table 2 Weight, visceral fat, visceral fat/weight ratio, and liver/body weight ratio in the groups
Control group HFD group Acipimox group
Weeks 8 w 16 w 24 w 8 w 16 w 24 w 8 w 16 w 24 w
Weight (g) 419.7 ± 8.6 500.5 ± 9.8 582.6 ±
16.5
470.2 ± 17.8 646.2 ±
15.5**
690.5 ± 29.5* 456.0 ± 16.6 615.3 ±
22.2**
682.7 ± 20.2*




















3.5 ± 0.2 3.4 ± 0.3 3.6 ± 0.3 5.3 ± 0.3** 8.3 ± 0.7** 10.9 ± 0.5**## 5.5 ± 0.4** 7.5 ± 0.7** 8.7 ± 0.4**
Liver/body weight
(%)
2.7 ± 0.1 2.5 ± 0.1 2.6 ± 0.1 3.2 ± 0.1* 3.3 ± 0.2* 3.1 ± 0.1** 3.1 ± 0.1* 3.1 ± 0.1* 3.0 ± 0.1*
Data are shown as means ± SEM. *p < 0.05 versus the corresponding Control group; **p < 0.01 versus the corresponding Control group; #p < 0.05 versus the
corresponding Acipimox group; ## p < 0.01 versus the corresponding Acipimox group; HFD: high-fat diet
Table 3 Values of serum TC, TG, and FFAs in the studied groups
Control group HFD group Acipimox group
Weeks 8 w 16 w 24 w 8 w 16 w 24 w 8 w 16 w 24 w
TC (mmol/L) 1.05 ± 0.16 1.17 ± 0.15 1.24 ± 0.15 1.36 ± 0.08 1.81 ± 0.13*# 1.93 ± 0.17*# 1.18 ± 0.08 1.22 ± 0.11 1.21 ± 0.16
TG (mmol/L) 0.25 ± 0.04 0.30 ± 0.05 0.38 ± 0.05 0.84 ± 0.07**## 1.13 ± 0.14**# 0.84 ± 0.08**# 0.44 ± 0.06 0.65 ± 0.08 0.50 ± 0.07
FFAs (mmol/L) 0.29 ± 0.07 0.29 ± 0.07 0.34 ± 0.06 0.43 ± 0.07 0.90 ± 0.06**## 0.91 ± 0.10**# 0.34 ± 0.05 0.32 ± 0.07 0.56 ± 0.10
Data are shown as means ± SEM. *p < 0.05 versus the corresponding Control group; **p < 0.01 versus the corresponding Control group; #p < 0.05 versus the
corresponding Acipimox group; ##p < 0.01 versus the corresponding Acipimox group, HFD, high-fat diet, TC, Total cholesterol, TG triglycerides, FFAs free fatty acids
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DGAT2 protein expression level had increased by 61 % and
39 % (HFD group) and by 48 % and 58 % (Acipimox
group), respectively. No significant differences were ob-
served in the DGAT2 protein level between the HFD and
Acipimox groups at any time point. The protein expression
level of CPT-1a was markedly reduced in the HFD group
compared with the Control group at 24 weeks, although it
did not differ significantly between the two groups at 8 and
16 weeks. The hepatic CPT-1a concentration can be effect-
ively maintained by acipimox feeding and was similar be-
tween the Acipimox and Control groups (Fig. 2).
Hepatic histological changes
Representative histological images of H&E-stained liver
sections are shown in Fig. 3. The HFD successfully in-
duced hepatic steatosis, and HFD-fed rats displayed
prominent hepatic steatosis (steatosis score: 2.25 ± 0.2)
at the end of 8 weeks. At 24 weeks, the liver steatosis
score was 2.6 ± 0.2 and was accompanied by ballooned
hepatocytes and mild to moderate inflammatory cell in-
filtration. In the HFD group, the NAFLD activity score
(NAS), a score that reflects the pathological severity of
the liver, gradually increased from 2.3 ± 0.2 at 8 weeks to
3.5 ± 0.2 at 24 weeks (p < 0.05). The Acipimox-treated
rats demonstrated HFD-induced hepatic steatosis (stea-
tosis score: 2.1 ± 0.1 at 8 weeks and 2.4 ± 0.2 at 24 weeks),
but ballooned hepatocytes were not observed in liver
sections, and inflammation was less severe and less
prevalent than that observed in the HFD group at
24 weeks (NAS: 2.6 ± 0.3; p < 0.05 versus HFD group).
No rats in any treatment showed centrilobular or perisi-
nusoidal fibrosis with Masson’s trichrome stain, and the
liver sections of the Control group did not display any
histological abnormalities.
Discussion
At present, numerous dietary and/or genetic methods can
be used to induce animal models, which can simulate the
human condition of NAFLD in many aspects [13]. An
HFD is one of these methods. In addition to hepatic stea-
tosis, an HFD can often induce insulin resistance, lipid
metabolism disorders, and other metabolic syndrome
components with pathophysiology that is more similar to
that observed in human NAFLD than that generated by
other animal models of NAFLD [13, 14]. In this study, we
fed eight-week-old male Wistar rats high-fat chow, and
after 8 to 24 weeks of dietary treatment, the rats in the
HFD group exhibited increased body weight, visceral fat
mass, visceral fat/body weight ratio and liver/body weight
ratio when compared with the levels in the age-matched
control rats. HFD treatment also caused significant incre-
ments in the serum TC, TG level, elevated hepatic TG
Fig. 1 Time-dependent changes of liver TGs (a) and FFAs (b). Data are shown as means ± SEM; *p< 0.05 versus the corresponding Control group; **p<
0.01 versus the corresponding Control group; ##p< 0.01 versus the corresponding Acipimox group; HFD: high-fat diet group; TGs: triglycerides; FFAs: free
fatty acids
Table 4 Values of hepatic MDA and GSH-Px in the studied groups
Control group HFD group Acipimox group
Weeks 8 w 16 w 24 w 8 w 16 w 24 w 8 w 16 w 24 w
hepatic MDA (nmol/
mg)




2.01 ± 0.23 4.15 ± 0.28** 3.62 ± 0.52














Data are shown as means ± SEM. *p < 0.05 versus the corresponding control group; **p < 0.01 versus the corresponding Control group; #p < 0.05 versus the
corresponding Acipimox group; ##p < 0.01 versus the corresponding Acipimox group, HFD high-fat diet, MDA malondialdehyde, GSH-Px glutathione peroxidase
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content and marked lipid droplet deposition in the liver
sections, suggesting that the model of obesity accompan-
ied by NAFLD was successfully induced in this study.
It is interesting to note that after 8 weeks of dietary
treatment, the HFD group exhibited a 3.4-fold increase
in serum TG level and a 4.3-fold increase in hepatic TG
content compared with the levels in control rats. How-
ever, the increase in serum FFAs was only 48 %, and no
significant change in hepatic FFA content was observed
in HFD-fed rats compared with normal chow-fed rats.
These findings suggest that for the first 8 weeks of the
HFD, circulating FFAs were normally converted to TGs
in the liver and were stored in adipose tissue, the liver,
and other tissues, resulting in increases in body weight
and fat mass. At this time, the liver enzyme levels were
normal, although the liver/body weight ratio was in-
creased and the liver tissue sections indicated microvesi-
cular steatosis, which are consistent with signs of fatty
liver.
As the HFD treatment progressed, this trend was re-
versed. By 24 weeks, the increase in serum TG level in
the HFD group was only 2.2-fold that of normal rats,
whereas the hepatic TG content was only increased 2.4-
fold compared with normal rats. However, the serum
FFA levels were 2.7 times higher and the liver FFA con-
tent increased by 57 % in HFD-fed rats compared with
Fig. 2 Hepatic protein expression levels of DGAT2 (a) and CPT-1a (b) in the studied groups. Left, protein level of DGAT2, CPT-1a and β-actin in rats liver
treated as indicated. Right, densitometry quantification of DGAT2 and CPT-1a protein expression levels normalized to β-actin. Experiments were
repeated three times. Data are shown as means ± SEM (n = 5-7). *p < 0.05 versus the corresponding Control group; **p < 0.01 versus the corresponding
Control group; #p < 0.05 versus the corresponding Acipimox group; HFD: high-fat diet group; DGAT2: diacylglycerol acyltransferase 2; CPT-1a: carnitine
palmitoyltransferase 1a
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the Control group. We propose that the main mechan-
ism for these changes at 24 weeks might be due to an
impaired ability of the liver to synthesize TGs, resulting
in significantly elevated serum and hepatic FFAs levels.
In addition, at this time point, the serum ALT levels in
the HFD group were elevated, and the NAS was 3.5 ±
0.2, which suggest the possibility of steatohepatitis. Sev-
eral in vivo and in vitro studies have indicated that hep-
atic TG deposition may not be harmful; rather, it may
represent a protective mechanism against FFA-induced
lipotoxic liver injury by storing FFAs in the form of TGs
[6, 7, 15]. To further study the role of an elevated serum
FFA level on NASH, we treated the HFD-fed rats with
acipimox to reduce plasma FFA levels by inhibiting lip-
olysis. These results showed that the serum FFA and TG
concentrations in the Acipimox group were significantly
lower than those in the HFD group. Although the Acipi-
mox group did not significantly differ from the HFD
group in liver TG content, the content of hepatic FFAs
in the Acipimox group was consistent with that of the
Control group. Despite the increase in the liver/body
weight ratio, the Acipimox group did not show any obvi-
ous changes in serum ALT levels, and the NAS in the
Acipimox group was also lower than that of the HFD
group, indicating that acipimox treatment reduced liver
damage in HFD-fed rats. These findings suggest that in-
creased serum and liver FFAs concentrations rather than
TGs may be a key link between obesity and the develop-
ment of NAFLD.
An elevated circulating FFA level is one of the clinical
characteristics of subjects with obesity/metabolic syndrome.
Under conditions of insulin resistance, defects in the β-
oxidation of FFAs are observed. Elevated FFA levels in the
liver can cause hepatocyte injury via the formation of vari-
ous toxic metabolites, such as ceramides, diacylglycerols,
and lysophosphatidylcholine [16]. These metabolites can re-
sult in mitochondria dysfunction via multiple methods,
such as inhibiting the mitochondrial oxidative respiratory
Fig. 3 Liver sections stained with haematoxylin and eosin from rats fed with regular chow for 8 weeks (a), 16 weeks (d), or 24 weeks (g); from
rats fed an HFD for 8 weeks (b), 16 weeks (e), or 24 weeks (h); or from rats fed an HFD + acipimox for 8 weeks (c), 16 weeks (f), or 24 weeks (i).
Original magnification, 200×, and the length of the calibration bar is 50 um. HFD: high-fat diet
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chain [17], activating NADPH oxidase, or depolarising the
mitochondrial membrane [18, 19], which can result in in-
creased ROS production, thereby enhancing oxidative
stress-induced liver injury. It has been shown that MDA,
an index of oxidative stress, can damage cells and tissues,
whereas GSH-Px, one of the body’s endogenous antioxi-
dants, can protect hepatocytes against oxidative damage via
chemical or enzymatic reactions. In our study, hepatic
MDA levels were obviously elevated and progressively in-
creased in the HFD group over 24 weeks compared with
the Control group. Furthermore, the decrease in hepatic
GSH-Px activity occurred at 8 weeks in the HFD group.
The hepatic MDA level in the Acipimox group was similar
to that of the control group and was markedly lower than
that of the corresponding HFD group. Taken together, these
findings suggest that a high serum FFA level may induce
steatohepatitis by enhancing oxidative stress. When the
level of FFAs is lowered with acipimox, hepatic oxidative
stress levels decrease, thereby reducing liver damage and
delaying the occurrence of NASH.
In the NAFLD state, the synthesis of hepatic TGs was
increased. Although the classic “two hit” theory considers
hepatic TG deposition to be a prerequisite for the devel-
opment of NASH, emerging studies have suggested that
TG accumulation may only be an “innocent bystander” or
even a protective mechanism in the progression of
NAFLD to NASH [7, 20]. In our study, the serum and
liver FFA levels progressively increased in the HFD group
over 24 weeks, but TG accumulation in the HFD group
markedly decreased from 4.3-fold at 8 weeks to 2.4-fold at
24 weeks compared with the Control group, indicating
that the ability of the liver to synthesize TGs is impaired
with progression of the disease.
To further explore the potential mechanism that in-
duces the change in liver TG content, we measured the
hepatic protein expression levels of the TG synthesis-
related enzyme DGAT2. DGAT2 is the rate-limiting en-
zyme in TG synthesis and plays an important role in the
development of fatty liver diseases [21]. Previous studies
have shown that the levels of DGAT2 mRNA/protein
are elevated in the NAFLD state [22, 23]. The results of
the present study are consistent with those of previous
studies. Compared with the Control group, the HFD
group exhibited a pronounced increase in DGAT2 pro-
tein level. Regarding the HFD group, no significant
change in the expression of DGAT2 protein was ob-
served during the course of the disease, and thus we
speculate that an impairment of TG synthesis due to a
decrease in DGAT2 protein expression was unlikely.
It is well known that CPT-1a is a gated enzyme that
regulates mitochondrial β-oxidation in the liver. Previous
studies have revealed conflicting results regarding the
change in CPT-1a in NAFLD [24, 25]. The present study
indicated that CPT-1a expression was similar between
the HFD and Control groups at 8 weeks. By 24 weeks,
CPT-1a expression was markedly decreased in HFD-fed
rats. After treatment with acipimox, the level of CPT-1a
protein expression was similar to that of the Control
group, suggesting that during the progression of the dis-
ease, the oxidative capacity of mitochondrial fatty acids
declines and that lowering hepatic FFAs levels may
maintain the function of mitochondrial lipid oxidation,
thus maintaining the balance of energy metabolism. We
speculate that the decline in the oxidative capacity of
mitochondrial lipids and oxidative stress-induced mito-
chondrial damage could jointly cause a decrease in ATP
synthesis, resulting in an energy deficit in TG synthesis
and subsequently impaired TG synthesis.
Finally, our study demonstrated that declining elevated
serum FFAs levels were beneficial in preventing the con-
version of simple steatosis to steatohepatitis. Nonphar-
macologic interventions such as weight loss in obese
patients, reduced carbohydrate intake, especially intake
of high glycemic and high fructose foods, and aerobic
exercise should be first-line choices. A number of
agents, such as fibrates and nicotinic acid, can be used
to reduce serum FFAs levels if nonpharmacologic inter-
ventions fail. In addition, nutraceuticals and functional
food ingredients (such as fish oil and soyabean) that are
beneficial to the lipid profile may reduce the risk of fatty
liver by acting in parallel to pharmacologic therapy, as
adjuvants in case of failure or in situations where
pharmacologic therapy cannot be used [24, 26].
The main limitation of the current study is that we
failed to induce NASH, mainly due to the limitations of
the HFD-induced NAFLD model [13]. Although this
drawback limits the extension of our results, we ob-
served that the degree of liver damage was gradually in-
creased as the HFD feeding period progressed via
changes in NAS and serum ALT levels, and the hepatic
FFA content and oxidative stress level showed pro-
nounced changes. Therefore, we speculate that these
changes should be more pronounced when the disease
progresses to NASH.
Conclusions
This study indicated that during the development of
NAFLD, FFA levels increased significantly and were
accompanied by an increase in oxidative stress. Then a
reduction in FFA levels was observed, which can effect-
ively reduce oxidative stress and liver injury. These find-
ings suggest that although liver TG deposition is the
primary characteristic of NAFLD, it may be an “innocent
bystander” or a protective mechanism in the develop-
ment of NAFLD. However, FFAs and their metabolites
are likely, at least in part, the pivotal factor that pro-
motes the development of NAFLD. Future studies are
Liu et al. Lipids in Health and Disease  (2016) 15:27 Page 8 of 9
needed to obtain definitive results regarding this issue. If
this is the case, then treatments should focus on how to
effectively reduce the lipotoxicity of FFAs rather than
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